loading page

Can Tenofovir diphosphate be a candidate drug for Sars-Cov2? First clinical perspective
  • Omer Kutlu
Omer Kutlu
Usak University, School of Medicine
Author Profile

Abstract

COVID-19 pandemic continues to spread across the world in late September 2020. To date, total cases of COVID-19 exceed 33 million including 996.342 deaths according to the WHO data. Although hydroxychloroquine, oseltamivir, remdesivir, favipiravir have been reported as an anti-SARS-CoV-2 effect, it is still unclear the fully effective protective drug and treatment. Herein, we report a woman under Tenofovir diphosphate who live and close contact with his COVID-19 positive husband. Although she had close contact with his husband without measure in the home she did not show any symptoms and signs of COVID-19 and her PCR test along with antibody test negative. Given the high reproduction number of SARS-CoV-2 and long-term close contact of the case, it can be speculated that Tenofovir could interfere with the transmission of COVID-19.

Peer review status:Published

29 Sep 2020Submitted to International Journal of Clinical Practice
30 Sep 2020Assigned to Editor
30 Sep 2020Submission Checks Completed
04 Oct 2020Reviewer(s) Assigned
05 Oct 2020Review(s) Completed, Editorial Evaluation Pending
21 Oct 2020Editorial Decision: Accept
Jan 2021Published in International Journal of Clinical Practice volume 75 issue 1. 10.1111/ijcp.13792